Accumulating evidence suggests that leptin is expressed at higher levels in obese women and stimulates cell migration in epithelial cancers. However, the biology of ovarian cancer is different from others, mainly due to the production of estrogens because of the involvement of ovarian tissue, which is the main source of estrogens; as a result, the levels are at least 100- to 1000-fold higher than normal circulating levels. Thus, ovarian cancer tissues are exposed to 17β-estradiol, which promotes ovarian cancer cell migration and may modulate the effect of other hormones. Therefore, this study investigated the effects of 17β-estradiol (1 nmol/L) with leptin (1-40 ng/mL) at physiological levels, on the migration of OVCAR-3 and SKOV-3 ovarian cancer cells, and the expression levels and activity of metalloproteinases (MMPs) 2 and 9. Here, we found that leptin stimulated ovarian cancer cell line migration, which is mediated via the expression and activity of MMP-9 in the OVCAR-3 but not in the SKOV-3 cells. After the administration of 17β-estradiol and leptin, we observed antagonistic effects of 17β-estradiol on leptin-induced OVCAR-3 cell migration and MMP-9 expression and activity. Moreover, the antagonistic effect of 17β-estradiol on leptin-induced cancer cell migration was reversed by pretreatment of the cells with the phosphatidylinositol 3-kinase (PI3K) pathway inhibitor. Taken together, our results, for the first time, show that in ovarian cancer cells ObR+/ER+, 17β-estradiol has an antagonistic effect on leptin-induced cell migration as well as MMP-9 expression and activity, which is mediated by the PI3K pathway.
OweckiMNikischEMiczkeAPupek-MusialikDSowińskiJ. Leptin, soluble leptin receptors, free leptin index, and their relationship with insulin resistance and BMI: high normal BMI is the threshold for serum leptin increase in humans. Horm Metab Res. 2010;42(8):585–589.
2.
FrühbeckG. Intracellular signaling pathways activated by leptin. Biochem J. 2006;393(pt 1):7–20.
3.
PtakAGregoraszczukEL. Bisphenol A induces leptin receptor expression, creating more binding sites for leptin, and activates the JAK/Stat, MAPK/ERK and PI3K/Akt signaling pathways in human ovarian cancer cell. Toxicol Lett. 2012;210(3):332–337.
4.
UddinSBuRAhmedM. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer. 2009;8:74.
5.
ChoiJHLeeKTLeungPC. Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth. Carcinogenesis. 2011;32(4):589–596.
6.
PtakAKolaczkowskaEGregoraszczukEL. Leptin stimulation of cell cycle and inhibition of apoptosis gene and protein expression in OVCAR-3 ovarian cancer cells. Endocrine. 2013;43(2):394–403.
7.
GoetzeSBungenstockACzupallaC. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension. 2002;40(5):748–754.
8.
SaxenaNKSharmaDDingX. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007;67(6):2497–2507.
9.
GuoSGonzalez-PerezRRNotch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer. PLoS One. 2011;6(6):e21467.
10.
FarleyJSmithLMDarcyKM. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res. 2003;63(6):1235–1241.
11.
SymowiczJAdleyBPGleasonKJ. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res. 2007;67(5):2030–2039.
12.
KennyHALengyelE. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle. 2009;8(5):683–688.
13.
LindgrenPRBäckströmTCajanderS. The pattern of estradiol and progesterone differs in serum and tissue of benign and malignant ovarian tumors. Int J Oncol. 2002;21(3):583–589.
14.
SantosMJGarcía-LáezVBeltrán-TorregrosaD. Hormonal and molecular characterization of follicular fluid, cumulus cells and oocytes from pre-ovulatory follicles in stimulated and unstimulated cycles. Hum Reprod. 2012;27(6):1596–605.
15.
PtakAHoffmannMGrucaIBarćJ. Bisphenol A induces ovarian cancer cell migration via the MAPK and PI3K/Akt signaling pathways. Toxicol Lett. 2014;229(2):357–365.
16.
ChenVWRuizBKilleenJLCotéTRWuXCCorreaCN. Pathology and classification of ovarian tumors. Cancer. 2003;97(10 suppl):2631–2642.
17.
LivakKJSchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
18.
KimSHNagalingamASaxenaNKSinghSVSharmaD. Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis. 2011;32(3):359–367.
19.
KikkawaFTamokoshiKNawaAShibataKYamagataSSuganumaN. Positive correlation between inhibitors of matrix metalloproteinase 1 and matrix metalloproteinases in malignant ovarian tissues. Cancer Lett. 1997;120(1):109–115.
20.
HuangLWGarrettAPBellDAWelchWRBerkowitzRSMokSC. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol. 2000;77(3):369–376.
21.
RauvalaMAglundKPuistolaU. Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression. Int J Gynecol Cancer. 2006;16(3):1297–302.
22.
SchmalfeldtBPrechtelDHärtingK. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001;7(8):2396–2404.
23.
HuXLiDZhangWZhouJTangBLiL. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet. 2012;286(6):1537–1543.
24.
SchroeterMRSteinSHeidaNM. Leptin promotes the mobilization of vascular progenitor cells and neovascularization by NOX2-mediated activation of MMP9. Cardiovasc Res. 2012;93(1):170–180.
25.
BilbaoMGDi YorioMPFalettiAG. Differential effects of leptin on ovarian metalloproteinases and their tissue inhibitors between in vivo and in vitro studies. J Endocrinol. 2011;209(1):65–74.
26.
YanYLiuHWenH. The novel estrogen receptor GPER regulates the migration and invasion of ovarian cancer cells. Mol Cell Biochem. 2013;378(1-2):1–7.
27.
SongJFadielAEdusaV. Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett. 2005;220(1):57–65.
28.
MungenastFThalhammerT. Estrogen biosynthesis and action in ovarian cancer. Front Endocrinol (Lausanne). 2014;5:192.
29.
LauKMMokSCHoSM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A. 1999;96(10):5722–5727.
30.
OkumuraMYamamotoMSakumaH. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. Biochim Biophys Acta. 2002;1592(2):107–116.
31.
AhnJHChoiYSChoiJH. Leptin promotes human endometriotic cell migration and invasion by up-regulating MMP-2 through the JAK2/STAT3 signaling pathway. Mol Hum Reprod. 2015;21(10):792–802.
32.
KatoSAbarzua-CatalanLTrigoC. Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women. Oncotarget. 2015;6(25):21100–21119.
33.
CalleEERodriguezCWalker-ThurmondKThunMJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–1638.
34.
RenehanAGRobertsDLDiveC. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008;114(1):71–83.
35.
OlsenCMNagleCMWhitemanDC. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer. 2013;20(2):251–262.
